|Bid||2.0000 x 45900|
|Ask||2.0500 x 3100|
|Day's Range||2.0000 - 2.0500|
|52 Week Range||1.3500 - 22.1000|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jul 25, 2018 - Jul 30, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||4.00|
Versartis (VSAR) stock rose 48.3% in the week of June 1–8. Versartis had consistent growth during the week, with 6.9% and 9.7% growth on June 4 and June 5, respectively. VSAR stock has risen ~50.9% over the last month. On June 4, Versartis entered into a merger agreement with Aravive Biologics.
LONDON, UK / ACCESSWIRE / June 5, 2018 / If you want access to our free research report on Sarepta Therapeutics, Inc. (NASDAQ: SRPT), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=SRPT as the Company's latest news hit the wire. On June 01, 2018, the Company announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a negative opinion against approval for EXONDYS® (eteplirsen) for treatment of patients with Duchenne muscular dystrophy (DMD).
LONDON, UK / ACCESSWIRE / June 5, 2018 / If you want a free Stock Review on VSAR sign up now at www.wallstequities.com/registration. This Tuesday, WallStEquities.com has initiated reports coverage on the following Biotechnology equities: Versartis Inc. (NASDAQ: VSAR), Vertex Pharmaceuticals Inc. (NASDAQ: VRTX), 22nd Century Group Inc. (NYSE AMER: XXII), and Abeona Therapeutics Inc. (NASDAQ: ABEO).
Shares of Versartis Inc. soared 24% in active premarket trade Monday, after the biopharmaceutical company announced a deal to merge with privately held Aravive Biologics Inc., to create a company focused on developing cancer treatments. Aravive's lead development candidate AVB-S6-500 is in a phase 1 trial for the treatment of ovarian cancer. After the deal closes, the company will operate under the Aravive Inc. name, and will continue to trade on Nasdaq, but under a new ticker symbol to be determined at a later date.
Versartis, Inc. (VSAR), and Aravive Biologics, Inc., today jointly announced that they have entered into a definitive agreement under which Aravive will merge with a wholly owned subsidiary of Versartis in an all-stock transaction. The transaction will result in a clinical stage, Nadsaq-listed company, based in Houston, Texas, focused on the development of innovative oncology therapeutics.
The Menlo Park, California-based company said it had a loss of 25 cents per share. The company's shares closed at $1.50. A year ago, they were trading at $17.50. _____ This story was generated by Automated ...
MENLO PARK, Calif., May 08, 2018-- Versartis, Inc., an endocrine-focused biopharmaceutical company, today announced financial results for the first quarter ended March 31, 2018.. “We have undertaken additional ...
NEW YORK, April 20, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
Versartis Inc (NASDAQ:VSAR) files its latest 10-K with SEC for the fiscal year ended on December 31, 2017.
On a per-share basis, the Menlo Park, California-based company said it had net income of 87 cents. The biopharmaceutical company posted revenue of $40,000 in the period. For the year, the company reported ...
Investors in Versartis (VSAR) need to pay close attention to the stock based on moves in the options market lately.
NEW YORK, NY / ACCESSWIRE / December 4, 2017 / It was an exciting day for biotech companies Ampio Pharmaceuticals and Versartis. Both stocks had big closes in the green. Ampio has engaged with LaVoieHealthScience ...
The Menlo Park, California-based company said it had a loss of $1.40 per share. The results did not meet Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research ...
NEW YORK, NY / ACCESSWIRE / September 25, 2017 / Shares of Exelixis saw losses on Friday after a downgrade from Leerink Partners. The stock was also downgraded last month by Deutsche Bank. Shares of Versartis ...